# Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

> **NCT03532698** · — · UNKNOWN · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer Stage IIIB
- Non-small Cell Lung Cancer Stage IV
- EGFR T790M

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03532698
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532698, "Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03532698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*